Amneal Pharmaceuticals Inc. has announced that its subsidiary, Amneal Pharmaceuticals LLC, has priced a private offering of $600 million in senior secured notes due 2032, with an interest rate of 6.875%. The offering was adjusted down from an initially planned $750 million, in conjunction with an increase in the term loan facility. Concurrently, Amneal plans to borrow $2.1 billion in new seven-year term B loans under a new term loan facility. The proceeds from these financial activities will be used to refinance existing term B loans, repay outstanding amounts under the ABL facility, and cover related expenses. The notes, offered at 100% of their principal amount, are expected to close on August 1, 2025, subject to customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.